Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
The health ministry’s new guidelines on ethical drug detailing activities took effect this April, requiring drug makers to properly store the daily work reports of their sales reps, and promptly present documents when required by regulatory authorities. Companies are scurrying…
To read the full story
Related Article
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- New Detailing Guidelines Take Effect on April 1; Q&A on Information Supply on Unapproved Drugs/Indications Issued
April 2, 2019
BUSINESS
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
- Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…